Skip to content
value.today

111

YI
$32 Mmarket cap on Aug 1, 2026-76.8% since Jan 2024
Compare
World rank
#22,804
Revenue
$1.8 B
For year ending December-2025
Net income
$-3 M
-0.2% margin
SEC filing
Employees
—

111 in brief

111 is a listed company in the Retail - Pharmacy industry, based in China. It was founded in 2010. Its market value was $32 M on 1 August 2026, which makes it the 22,804th largest listed company in the world and the 4,199th largest in China on this site. In the year to December 2025 it had sales of $1.8 B and a net loss of $3 M. Its largest product and service lines by sales in 2025 were B2B segment (98%), Drugs (93%) and Nutritional supplements (3%). Its shares trade under the symbol YI (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About 111

We face various legal and operational risks as a company based in and primarily operating in China. The PRC government has significant authority to exert influence on the ability of a China-based company, like us, to conduct its business, accept foreign investments or be listed on a U.S. stock exchange. For example, we face risks associated with regulatory approvals of offshore securities offerings, anti-monopoly regulatory investigations and actions, cybersecurity and data privacy compliance. The PRC government may also exert influence on our operations as it deems appropriate to further regulatory, political and societal goals. The PRC government has recently published new policies that affected our industry and we cannot rule out the possibility that it will in the future further release regulations or policies regarding our industry that could adversely affect our business, financial condition and results of operations. Any such action, once taken by the PRC government, could cause the value of such securities to significantly decline or in extreme cases, become worthless.

From the company's annual report filed with the US SEC: read the report

111 timeline

5 events, 2010–2023
  1. 2010
  2. 🏁
    · approximate
    Founded
  3. 2018
  4. 🔔
    · approximate
    Initial public offering on Nasdaq
  5. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  6. 2020
  7. 💰
    Revenue passed $1 billion
    FY2020 revenue of $1.3 billion, up from $568 million in FY2019.
  8. 2023
  9. 💰
    Record revenue of $2.1 billion
    FY2023, the highest of the 8 years on record.

Events of 111 from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$154 M$309 M$463 M$618 M2020202120222023202420252026

World rank over time

▼ down 9,892 places since 2020
2020-01-01: #10749#10,74920202021-01-01: #10528#10,52820212022-01-07: #17686#17,68620222022-12-25: #16599#16,59920222023-07-30: #16641#16,64120232024-01-05: #19808#19,80820242026-03-08: #10717#10,71720262026-08-01: #20641#20,6412026

Rank in China: #2,609 (Jan 2020) · #2,847 (Jan 2021) · #4,611 (Jan 2022) · #4,665 (Dec 2022) · #4,751 (Jul 2023) · #5,024 (Jan 2024) · #4,453 (Mar 2026) · #4,220 (Aug 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.0×
Price / book
—
Free cash flow yield
51.2%
Net margin (TTM)
-0.2%
Operating margin
-0.0%
Return on equity
—
Liabilities / assets
90.3%
Revenue growth
-9.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $260M, net income $-56M$260MFY18Fiscal year ending Dec 2019: revenue $568M, net income $-72M$568MFY19Fiscal year ending Dec 2020: revenue $1.3B, net income $-72M$1.3BFY20Fiscal year ending Dec 2021: revenue $1.9B, net income $-97M$1.9BFY21Fiscal year ending Dec 2022: revenue $2.0B, net income $-55M$2.0BFY22Fiscal year ending Dec 2023: revenue $2.1B, net income $-50M$2.1BFY23Fiscal year ending Dec 2024: revenue $2.0B, net income $-3M$2.0BFY24Fiscal year ending Dec 2025: revenue $1.8B, net income $-3M$1.8BFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$1.8B-9.0%$-0M$-3M-0.2%
Dec 2024$2.0B-6.3%$0M$-3M-0.1%
Dec 2023$2.1B+7.4%$-49M$-50M-2.4%
Dec 2022$2.0B+0.5%$-54M$-55M-2.8%
Dec 2021$1.9B+55.1%$-101M$-97M-5.0%
Dec 2020$1.3B+121.5%$-73M$-72M-5.7%
Dec 2019$568M+118.5%$-71M$-72M-12.7%
Dec 2018$260M—$-58M$-56M-21.4%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$17M$1M$16M$-0.05—
Dec 2024$36M$2M$34M$-0.05—
Dec 2023$-63M$1M$-64M$-0.33—
Dec 2022$-3M$5M$-8M$-0.36—
Dec 2021$-108M$10M$-118M$-0.63—
Dec 2020$-18M$4M$-22M$-0.42—
Dec 2019$-74M$3M$-76M$-0.44—
Dec 2018$-50M$2M$-52M$-0.56—

SEC filings

Official filings of 111 with the US Securities and Exchange Commission.

Annual results

Revenue
$1.8 B
Operating income
$-0 M
Net income
$-3 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$315 M
Total liabilities
$284 M
Total equity
$-100 M

As of December-2025

Top 11 institutional investors in 111#

As of Sep 30, 2026
11 institutions held 45,943 shares (about 0.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 0.5%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 11 largest institutional investors in 111
#InstitutionShares heldChange (shares)% heldValueFiled
1Citadel Advisors LLC26,260+8,921 (+51.45%)0.30%$0 MNov 16, 2026
2Renaissance Technologies LLC12,714-200 (-1.55%)0.15%$0 MNov 12, 2026
3Serenus Wealth Advisors, LLC3,977-343 (-7.94%)0.05%$0 MNov 10, 2026
4UBS Group AG1,477-120 (-7.51%)0.02%$0 MNov 10, 2026
5Nuveen, LLC599New0.01%$0 MNov 10, 2026
6Citigroup Inc531New0.01%$0 MNov 4, 2026
7SBI Securities Co., Ltd.1490 (0.00%)0.00%$0 MOct 22, 2026
8Morgan Stanley1130 (0.00%)0.00%$0 MNov 13, 2026
9Jpmorgan Chase & Co71+24 (+51.06%)0.00%$0 MNov 12, 2026
10Strategic Financial Concepts, LLC30New0.00%$0 MNov 16, 2026
11Rhumbline Advisers220 (0.00%)0.00%$0 MNov 10, 2026

Mutual funds holding 111#

1 funds hold shares worth $0 M. Since their previous reports 0 added shares and 0 sold.
Mutual funds holding 111
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC2,444$0 M—<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at 111#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
0
0 purchases, 0 insiders
Sold, 12 months
267 K
36 sales, 3 insiders
Net, 12 months
-267 K
open market only
Insiders on file
4
since
-$214 K$0May 2026: bought $0 (0 trades), sold $30 K (18 trades)May 26Jun 2026: bought $0 (0 trades), sold $214 K (15 trades)JunSep 2026: bought $0 (0 trades), sold $23 K (3 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
111: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Yang Luke ChenDirectorSell-38,1200.1807 Klocal413,342Form 4
filed Yang Luke ChenDirectorSell-44,0000.1808 Klocal451,462Form 4
filed Yang Luke ChenDirectorSell-44,0000.1808 Klocal451,462Form 4
filed Yang Luke ChenDirectorSell-44,0000.23010 Klocal495,462Form 4
filed Yang Luke ChenDirectorSell-44,0000.23010 Klocal495,462Form 4
filed Yang Luke ChenDirectorSell-44,0000.23010 Klocal495,462Form 4
filed Jian David SunDirectorSell-58,8000.23014 Klocal413,211Form 4
filed Yang Luke ChenDirectorSell-49,9200.23011 Klocal539,462Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars

Markets and events: 111#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
13,122
1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 2-for-1 split

Trading halts

  • 2026-09-10 18:32 UTC, code LUDP, resumed 18:37 UTC
  • 2026-09-08 13:49 UTC, code LUDP, resumed 13:59 UTC
  • 2026-08-31 17:57 UTC, code LUDP, resumed 18:02 UTC
  • 2026-01-30 20:34 UTC, code LUDP, resumed 20:39 UTC
  • 2026-01-30 20:09 UTC, code LUDP, resumed 20:29 UTC

Fails to deliver

  • : 324 shares at $2.85
  • : 3,734 shares at $3.83
  • : 3,157 shares at $3.76
  • : 802 shares at $3.42
  • : 1,407 shares at $3.33

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

111 scorecard#

Passes 6 of the 15 checks that could be worked out: strongest in profitability (2 of 4), weakest in growth (1 of 6). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-9.0%Revenue down 9.0% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-2.9%-2.9% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-2.9%-2.9% a year against Retail - Pharmacy's median of 0.4% (6 companies).
    • ✗Earnings per share grew in the newest year-0.05 vs -0.05Diluted EPS -0.05 in fiscal 2025 against -0.05 the year before (report's currency).
    • ✓Net income higher than five years earlier-$3 M-$3 M in fiscal 2025 against -$72 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability2 of 4
    • ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median-0.0%-0.0% against Retail - Pharmacy's median of -2.4% (7 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-0.0%-0.0% in fiscal 2025 against -2.7% in 2022.
  • Financial health2 of 4
    • ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.09 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-0.1×Operating income -0.1 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone3.35Z-score 3.35 (safe zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year1.3%Diluted shares up 1.3% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Retail - Pharmacy, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from 111's statements, beside the median of Retail - Pharmacy.

111: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-0.0%-2.4%
Net margin-0.2%-1.4%
Revenue growth, 3 years a year-2.9%0.4%
Revenue growth-9.0%8.3%
Free cash flow margin0.9%-0.3%

4of 8on the Piotroski tests of financial strength

  • Revenue fell 9.0% against the year before.
  • Net loss of $3 million, the 10th loss-making year in a row.
  • Shareholders' equity is negative: -$100 million.
  • Operating income covers the interest bill only -0.1 times.

111: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in CNY millions; per-share figures in CNY; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

111: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue12,55614,40114,94813,51712,4268,2033,9521,786959874
Cost of revenue11,83313,57214,09912,67711,8057,837r3,787r7456—
Gross profit723829849840621366165r104r8074
Selling and marketing259314448458513400341260190253
General and administrative6971224206207128124995361
Total costs and expenses12,55814,39915,29813,88813,0688,6764,4462,1861,2141,238
Operating income−2.42.1−350−371−642−473−494−400−254−364
Interest and finance income3.97.08.88.19.86.34.84.44.02.3
Interest expense and finance costs362820135.58.83.6—0.10.8
Provision for credit losses0000000———
Other non-operating income (expense)11−0.67.68.1153.20.8124.2−3.4
Income before tax−23−21−353−376−621−467−502−382−249−363
Income tax0.00.10.300000.0——
Net income including minority interests−23−21−353−376−621−467−502−382−249−363
Minority interests' share of net income−4.1−8.4−17−15−280−2.2−2.0−0.7−0.8
Net income attributable to shareholders———————−382−249−363
Earnings per share, basic-0.38-0.38-2.33-2.50-4.04-2.77-3.05-3.82-3.45-5.81
Earnings per share, diluted-0.38-0.38-2.33-2.50-4.04-2.77-3.05-3.82-3.45-5.81
Shares, weighted average (basic)174172169167166165164———
Shares, weighted average (diluted)174172169167166165164997272
Balance sheet
Cash and cash equivalents5114626046746611,190581854168374
Short-term investments50—50206183300—253294—
Receivables26041353748940416365292028
Inventory9981,3871,4191,4991,121767486211144—
Other current assets176.8r226282242312209161105—
Current assets2,1252,6502,9333,2362,8022,8731,4811,507730—
Property, plant and equipment213334488043302017—
Right-of-use (leased) assets44891041642349988———
Other intangible assets0.91.42.33.34.96.58.04.54.8—
Long-term investments——2.02.03.00.10.11111—
Total assets2,2002,7883,0893,4743,1463,0261,6101,546763—
Accounts payable1,2821,7211,5891,7651,3471,073444212128—
Current liabilities1,9542,3432,7452,7252,1301,630773315201—
Lease liabilities (non-current)3055631001666257———
Total liabilities1,9862,4072,8132,8262,2971,696836323201—
Retained earnings−3,950−3,884−3,819−3,427−3,010−2,340−1,883−1,384−1,004—
Shareholders' equity−702−643−583−415−1733577771,224−946—
Minority interests−19−16−115.92149−2.7−0.51.4—
Total equity−721−658−595−409−1524067741,224−945−688
Total liabilities and equity2,2002,7883,0893,4743,1463,0261,6101,546763—
Cash-flow statement
Depreciation and amortization12172241271412111512
Share-based compensation10202271621467654519.93.4
Cash from operating activities119263−447−23−689−117−512−343−204−389
Capital expenditure−4.5−15−9.8−32−63−26−20−14−6.8−5.3
Intangible assets bought——−0.0−0.1−0.1−0.3−4.6−0.4−0.1−1.6
Cash from investing activities−5437152−4760−32523844−36−268
Debt repaid———−250−15—————
Shares issued0.70.00.20.32.96.311—0.00.0
Shares bought back————−5.9−12−23———
Cash from financing activities−21−40620623741,07010997350148
Exchange-rate effect on cash————−3.5−8.19.712−1535
Change in cash43−105−93−44−558621−156686−206−472
Report20-F20-F20-F20-F/A20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What 111 sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$1.7 B99%
  • B2B segment$1.7 B98%
  • Drugs$1.6 B93%
  • Nutritional supplements$60 M3.5%
  • Other products$33 M1.9%
  • B2C segment$31 M1.8%
  • Medical supplies and devices$21 M1.2%
  • Service(total)$12 M0.7%
  • MP Service$8 M0.5%
  • Other Services$4 M0.2%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

How 111 compares in Retail - Pharmacy

  • Market cap$32 M · higher than 12% of 35
  • Revenue$1.8 B · higher than 35% of 38
  • Net margin-0.2% · higher than 23% of 36
  • Revenue growth-9.0% · higher than 20% of 11
  • Price / sales0.0× · lowest of 25
  • FCF yield51.3% · highest of 5

Peer comparison · Retail - Pharmacy

CompanyMarket capP/ENet marginRev. growth
111🇨🇳$32 M—-0.2%-9.0%
Tsuruha Holdings Inc.🇯🇵$6.9 B23.8×2.9%—
Alibaba Health Information Technology Limited🇭🇰$6.7 B24.0×5.7%—
Matsumotokiyoshi Holdings🇯🇵$6.2 B16.5×5.0%—
Yifeng Pharmacy Chain Co., Ltd.🇨🇳$4.3 B17.8×6.9%—
Raia Drogasil S.A.🇧🇷$4.1 B16.8×2.9%—
Selçuk Ecza Deposu Ticaret Ve Sanayi A.S.🇹🇷$3.7 B72.7×3.5%—
Sugi Holdings Co., Ltd.🇯🇵$3.3 B23.6×3.1%—
Cosmos Pharmaceutical Corporation🇯🇵$3.3 B19.5×3.1%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at 111? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show 111's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about 111? Suggest a correction